Majority of Diagnostic Laboratory Leaders Bet Big on Digital Pathology and AI

Survey of 360 senior professionals finds modernization is key to overcoming longstanding industry challenges

MIB Agents' Community of Families Has Awarded $2.5M in Grants to Research Pediatric Bone Cancer

MIB Agents, a leading pediatric osteosarcoma nonprofit, announced it has awarded $2.5 million in research grants through its OutSmarting Osteosarcoma program, which is powered by families honoring children affected by the disease. At its upcoming FACTOR Conference (June 26–28) in Salt Lake City, the organization will award $700,000 in grants to 10 scientists advancing less toxic, more effective treatments. The grants, which include four $100,000 Hero Grants and six $50,000 Hope Young Investigator Grants, reflect a unique collaboration between researchers and the osteosarcoma community, with families actively funding and participating in the review of scientific proposals.

Model Medicines Named to “Fierce 15” List for Transformative AI Drug Discovery Platform

Model Medicines has been named to Fierce Medtech’s 2025 “Fierce 15” list for its pioneering AI platform, GALILEO™, which integrates generative chemistry and novel target discovery to develop breakthrough therapeutics. The company recently achieved a 100% hit rate from a 53 trillion-compound screen, with multiple preclinical assets.

Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach

Phase IIa study results of Rentosertib were published simultaneously in Nature Medicine(IF = 58.7) and presented at the American Thoracic Society (ATS) 2025. Encouraging clinical data showed that patients receiving 60 mg QD Rentosertib experienced the greatest mean improvement in lung function, as measured by forced vital capacity (FVC), with a mean change of +98.4 mL, compared to a mean decline of -20.3 mL in the placebo group. Exploratory biomarkers analyses further validated the biological mechanism of TNIK, the novel target identified through a generative AI approach, supporting Rentosertib’s potential anti-fibrotic and anti-inflammatory effects. Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized medicine, and unlocking unprecedented opportunities to accelerate drug discovery and delivery. Despite growing adoption, only a few AI-discovered or AI-designed drug candidates have advanced to clinical trials, and even fewer have demonstrated clinical proof-of-concept.

TeleTracking and Palantir Partner to Transform Healthcare Operations with AI-Powered Insights

Inizio Evoke Announces Medical Leadership Evolution: Matthew Hoelzle Named Chief Medical Officer

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Sionna Therapeutics announces positive data from its Phase 1 clinical trials of SION-719 and SION-451, the company’s nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers, and the company’s next phase of clinical development.

Annual Cotiviti Client Conference Focuses on AI, Interoperability and Reducing Healthcare Costs

Industry Leading RBQM Event Returns for 2025

CluePoints, the premier sponsor of RBQMLive and provider of leading statistical and AI-driven software solutions, has announced the full agenda and expert speaker line up for the 4th annual, award-winning event, RBQMLive.

Tjoapack continues to expand its global infrastructure with strategic investments in injectable packaging and cold chain capabilities

BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement

BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement

Linus Health Study Champions Person-Centered Brain Health Assessments

Linus Health Study Champions Person-Centered Brain Health Assessments

Thermo Fisher Scientific Unveils Next-generation Mass Spectrometers at ASMS 2025 to Revolutionize Biopharma Applications and Omics Research

Orbitrap Astral Zoom and Orbitrap Excedion Pro deliver increased speed and sensitivity to set a new performance benchmark for high-resolution, accurate mass spectrometry

1upHealth Launches Prior Authorization Solution and Technology Partnerships to Support CMS Electronic Prior Authorization Mandate for Health Plans

Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director

The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics

Latest Nature Communications Study: AI-Enabled Development of Next-Generation ENPP1 Inhibitors for Innate Immune Modulation by Insilico Medicine

Publication showcases the capabilities of Insilico's advanced generative AI platform and integrated workflow in facilitating the rapid development of ISM5939, further demonstrating the potential of AI in drug discovery. Unlike direct STING agonists, ISM5939 precisely modulates the STING pathway within tumor tissues by targeting ENPP1, thereby restoring local immune activation and enhancing anti-tumor immune responses. For the first time, ENPP1 inhibitors have been shown to overcome dual resistance to immune checkpoint inhibitors and chemotherapy, offering a new therapeutic hope for patients with refractory tumors. Since the start of 2025, this marks Insilico Medicine’s third AI-driven drug discovery study published in a Nature sub-journal. Immune checkpoint inhibitors have transformed cancer treatment, providing clinical benefits for a wide range of malignancies. However, only ~10-35% of patients on these treatments achieve a meaningful and durable response, underscoring the urgent need for innovative therapeutic strategies.

Ambience Healthcare's AI Platform Surpasses Clinician Performance by 27% in Medical Coding, Powered by New OpenAI Breakthrough

Association for Molecular Pathology Releases Series of Reports Defining Core Bioinformatics Competencies for Clinical Diagnostic Laboratories

AMP announced the release of a three-part series of papers on core bioinformatics capabilities for professionals in clinical molecular diagnostic labs.

Nuclera and Cytiva collaborate to accelerate characterization of proteins for drug development

● Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactions ● Collaboration allows researchers to progress rapidly from DNA to purified and characterized protein, to facilitate insights into drug-target interactions ● Showcased at Discovery on Target and PEGS Europe conferences, detailing the production and characterization of Bruton’s Tyrosine Kinase, which is implicated in B-cell malignancies

Sapio Sciences Appoints Gordon McCall as Chief Operating Officer to Drive Global Operational Excellence

Sapio Sciences, the science-aware™ lab informatics platform, today announced the promotion of Gordon McCall to Chief Operating Officer (COO). McCall has served as the company’s Chief Financial Officer (CFO) since 2022 and brings a proven track record of leadership, strategic execution, and operational acumen.